Mekonos, a San Francisco, CA-based biotech company launching a system-on-a-chip (SoC) for targeted ex vivo gene engineering, completed a $4.6m financing round.
The round was led by Novartis AG with participation from institutional VCs including Hike Ventures, CRCM Ventures and existing investors Good AI Capital and previous lead Elementum Ventures.
The company will use the new capital to accelerate the SoC platform for its current and new commercial partnerships.
Led by Anil Narasimha, PhD, Co-Founder and CEO, Mekonos is a biotech company advancing a gene engineering platform SoC platform, with IP from Stanford University, which allows for molecular delivery in gene editing and synthetic biology. The platform helps companies increase capacity, accelerate discoveries, and develop new pre-clinical assets in the emerging cell and gene therapy space.
The company recently completed pilots with key top pharmaceutical companies and research institutes that demonstrated high efficacy of modified gene expression and cell viability. They are now preparing to expand existing partnerships and engage in new ones.